Advertisement

Acromegaly and Gigantism

  • C. R. Kannan
Part of the Clinical Surveys in Endocrinology book series (CSED, volume 1)

Abstract

Acromegaly is a fascinating, awesome disorder caused by sustained hypersecretion of growth hormone. The term gigantism is used to denote the disorder when its onset precedes epiphyseal closure. Acromegaly was probably known to ancient Egyptians, as early as the thirteenth century B. c.1 Gigantism had fascinated Greek mythologists, who promulgated the notion that those afflicted with this disorder were favored by the Gods. The biblical tale of David and Goliath has strong undercurrents of the possibility that Goliath, the giant, suffered from bitemporal hemianopsia (due to a pituitary tumor), which made him unable to see the stone from David’s sling that came from the side and slew him.2,3

Keywords

Growth Hormone Pituitary Adenoma Growth Hormone Level Acromegalic Patient Pituitary Apoplexy 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Singer S, Hilgard HR: In The Biology of People. WH Freeman, San Francisco, 1978, p. 283.Google Scholar
  2. 2.
    Bollet AJ: Medical history in the bible. Part IV. Some metabolic and endocrine diseases. (Did Goliath have a pituitary tumor?) Resident Staff Physician 30:52, 1984.Google Scholar
  3. 3.
    Rabin D, Rabin PL: David, Goliath, and Smiley’s people. N Engl J Med 309:992, 1983.Google Scholar
  4. 4.
    Marie P: On two cases of acromegaly: Marked hypertrophy of the upper and lower limbs and the head. Rev Med 6:297, 1886.Google Scholar
  5. 5.
    Evans HM, Long JA: The effect of the anterior lobe of the pituitary administered intraperitoneally upon growth, maturity and oestrus cycle of the rat. Anat Rec 21:62, 1921.Google Scholar
  6. 6.
    Davidoff LM: Studies in acromegaly. The anamnesis and symptomatology in one hundred cases. Endocrinology 10:461, 1926.CrossRefGoogle Scholar
  7. 7.
    Alexander L, Appleton D, Hall R, et al: Epidemiology of acromegaly in the Newcastle region. Clin Endocrinol (Oxf) 12:71, 1980.CrossRefGoogle Scholar
  8. 8.
    Besser GM, Mortimer CH, Carr D, et al: Growth hormone release inhibiting hormone in acromegaly. Br Med J 1:352, 1974.PubMedCrossRefGoogle Scholar
  9. 9.
    Daughaday WH, Cryer PE: Growth hormone hypersecretion and acromegaly. Hosp Pract 13:75, 1978.PubMedGoogle Scholar
  10. 10.
    Cryer PE, Daughaday WH: Regulation of growth hormone secretion in acromegaly. J Clin Endocrinol Metab 29:386, 1969.PubMedCrossRefGoogle Scholar
  11. 11.
    Arafah BUM, Bradkey JS, Kaufman B, et al: Transsphenoidal microsurgery in the treatment of acromegaly and gigantism. J Clin Endocrinol Metab 50:578, 1980.PubMedCrossRefGoogle Scholar
  12. 12.
    Feingold KR, Goldfine ID, Weinstein PR: Acromegaly with normal growth hormone levels and pituitary histology. Case report. J Neurosurg 50:503, 1979.PubMedCrossRefGoogle Scholar
  13. 13.
    Asa SL, Bilbao JM, Kovacs K, et al: Hypothalamic neuronal hamartoma associated with pituitary growth hormone cell adenoma and acromegaly. Acta Neuropathol (Berl) 52:131, 1980.CrossRefGoogle Scholar
  14. 14.
    Rhodes RH, Dusseau JJ, Boyd AS Jr, et al: Intrasellar neural-adenohypophyseal choristoma. A morphological and immunocytochemical study. J Neuropathol Exp Neurol 41:267, 1982.PubMedCrossRefGoogle Scholar
  15. 15.
    Asa SL, Scheithauer BW, Bilbao JM, et al: A case for hypothalamic acromegaly: Clinicopathologic study of six patients with hypothalamic gangliocytomas producing growth hormone releasing factor. J Clin Endocrinol Metab 58:796, 1984.PubMedCrossRefGoogle Scholar
  16. 16.
    Lawrence AM, Goldfine ID, Kirstein L: Growth hormone dynamics in acromegaly. J Clin Endocrinol Metab 31:239, 1970.PubMedCrossRefGoogle Scholar
  17. 17.
    Cryer PE, Daughaday WH: Adrenergic modulation of growth hormone secretion in acromegaly: Suppression during phentolamine and phentoxamine-isoproterenol administration. J Clin Endocrinol Metab 39:658, 1974.PubMedCrossRefGoogle Scholar
  18. 18.
    Frohman LA: Diseases of the anterior pituitary. In Felig P, Baxter J, Broadus AE, Frohman LA (eds): Endocrinology and Metabolism. McGraw-Hill, New York, 1981, p. 204.Google Scholar
  19. 19.
    Hanew K, Kokubun M, Sasaki A, et al: The spectrum of pituitary growth hormone responses to pharmacological stimuli in acromegaly. J Clin Endocrinol Metab 51:292, 1980.PubMedCrossRefGoogle Scholar
  20. 20.
    Pieters GFFM, Romeijn JE, Smals AGH, et al: Somatostain sensitivity and growth hormone responses to releasing hormones and bromocryptine in acromegaly. J Clin Endocrinol Metab 54:942, 1982.PubMedCrossRefGoogle Scholar
  21. 21.
    Marcovitz S, Goodyer G, Guyda H, et al: Comparative study of human fetal, normal adult and somatotrophic adenoma pituitary function in tissue culture. J Clin Endocrinol Metab 54:1982, 1982.CrossRefGoogle Scholar
  22. 22.
    Tallo D, Malarkey WB: Adrenergic and dopaminergic modulation of growth hormone and prolactin secretion in normal and tumor-bearing human pituitaries in monolayer culture. J Clin Endocrinol Metab 53:1278, 1981.PubMedCrossRefGoogle Scholar
  23. 23.
    Nakayama I, Nickerson PA: Suppression of anterior pituitary in rats bearing a transplantable growth hormone and prolactin-secreting tumor (MtT.Wl0). Endocrinology 92:516,1973.PubMedCrossRefGoogle Scholar
  24. 24.
    Allen JP, Cook DM, Greer MA, et al: Evidence that acromegaly is not a hypothalamic disease. Trans Assoc Am Physicians 80:272, 1973.Google Scholar
  25. 25.
    Hoyte KM, Martin JB: Recovery from paradoxical growth hormone responses in acromegaly after transsphenoidal selective adenomectomy. J Clin Endocrinol Metab 41:656, 1975.PubMedCrossRefGoogle Scholar
  26. 26.
    Baskin DS, Boggan JE, Wilson CB: Transsphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. J Neurosurg 56:634, 1982.PubMedCrossRefGoogle Scholar
  27. 27.
    Faglia G, Parachi A, Ferrari C, et al: Evaluation of the results of transphenoidal surgery in acromegaly by assessment of the growth hormone response to thyrotropin-releasing hormone. Clin Endocrinol (Oxf) 8:873, 1978.CrossRefGoogle Scholar
  28. 28.
    Laws ER Jr, Piepgras DG, Randall RV, et al: Neurosurgical management of acromegaly. Results in 82 patients treated between 1972 and 1977. J Neurosurg 50:454, 1979.PubMedCrossRefGoogle Scholar
  29. 29.
    Schuster LD, Bantle JP, Oppenheimer JH, et al: Acromegaly: Reassessment of the long-term therapeutic effectiveness of transsphenoidal pituitary surgery. Ann Intern Med 95:172, 1981.PubMedGoogle Scholar
  30. 30.
    Guyda H, Robert F, Colle E, et al: Histologic ultrastructural and hormonal characterization of a pituitary tumor secreting both hGH and prolactin. J Clin Endocrinol Metab 36:531, 1973.PubMedCrossRefGoogle Scholar
  31. 31.
    Corenblum B, Sirek AMT, Horvath E, et al: Human mixed somatotrophic and lactotrophic pituitary adenoma. J Clin Endocrinol Metab 42:857, 1976.PubMedCrossRefGoogle Scholar
  32. 32.
    Kovacs K, Horvath E, Ezrin C: Pituitary adenomas. Pathol Annu 12(part 2):341, 1977.PubMedGoogle Scholar
  33. 33.
    Horvath E, Kovacs K: Pathology of the pituitary gland. In Ezrin C, Horvath E, Kaufman B, Kovacs K, Weiss MH (eds): Pituitary Diseases. CRC Press, Boca Raton, FL, 1980, pp. 1–83.Google Scholar
  34. 34.
    Horvath E, Kovacs K, Singer W, et al: Acidophil stem cell adenoma of the human pituitary. Arch Pathol Lab Med 101:594, 1977.PubMedGoogle Scholar
  35. 35.
    Horvath E, Kovacs K, Singer W, et al: Acidophil stem cell adenoma of the human pituitary. Clinico-pathological analysis of 15 cases. Cancer 47:761, 1981.PubMedCrossRefGoogle Scholar
  36. 36.
    Kovacs K, Horvath E: Pathology of pituitary adenomas. In Givens JR (ed): Hormone-Secreting Pituitary Tumors. Year Book, Chicago, 1982, p. 97.Google Scholar
  37. 37.
    Melmed S, Braunstein GD, Horvath E, et al: Pathophysiology of acromegaly Endocrinol Rev 4:271, 1983.CrossRefGoogle Scholar
  38. 38.
    Ballard HS, Frame B, Hartsock RJ: Familial multiple endocrine adenomapeptic ulcer complex. Medicine (Baltimore) 43:481, 1964.CrossRefGoogle Scholar
  39. 39.
    Rivier C, Vale W, Ling M: Stimulation in vivo of the secretion of prolactin and growth hormone by β-endorphin. Endocrinology 100:238, 1977.PubMedCrossRefGoogle Scholar
  40. 40.
    Matsushita N, Kato Y, Katakami H, et al: Stimulation of growth hormone release by vasoactive intestinal polypeptide from human pituitary adenomas in vitro. / Clin Endocrinol Metab 53:1297, 1981.CrossRefGoogle Scholar
  41. 41.
    Kaganowicz A, Farkouh NH, Frantz AG, et al: Ectopic human growth hormone in ovaries and breast cancer. J Clin Endocrinol Metab 48:5, 1979.PubMedCrossRefGoogle Scholar
  42. 42.
    Sparagana M, Phillips G, Hoffman C, et al: Ectopic growth hormone syndrome associated with lung cancer. Metabolism 20:730, 1971.PubMedCrossRefGoogle Scholar
  43. 43.
    Greenberg PB, Beck C, Martin TJ, et al: Synthesis and release of human growth hormone from lung carcinoma in cell culture. Lancet 1:350, 1972.PubMedCrossRefGoogle Scholar
  44. 44.
    Dabek JT: Bronchial carcinoid tumour with acromegaly in two patients. J Clin Endocrinol Metab 38:329, 1974.PubMedCrossRefGoogle Scholar
  45. 45.
    Melmed S, Ezrin C, Kovacs K, et al: Acromegaly due to secretion of growth hormone by an ectopic pancreatic islet-cell tumor. N Engl J Med 312:9, 1985.PubMedCrossRefGoogle Scholar
  46. 46.
    Caplan RH, Koob L, Avellera RM, et al: Cure of acromegaly by operative removal of an islet cell tumor of the pancreas. Am J Med 64:874, 1978.PubMedCrossRefGoogle Scholar
  47. 47.
    Frohman LA, Szabo M, Berelowitz M, et al: Partial purification and characterization of a peptide with growth hormone-releasing activity from extrapituitary tumors in patients with acromegaly. J Clin Invest 65:43, 1980.PubMedCrossRefGoogle Scholar
  48. 48.
    Leveston SA, McKeel DW Jr, Buckley PJ, et al: Acromegaly and Cushing’s syndrome associated with a foregut carcinoid tumor. J Clin Endocrinol Metab 53:682, 1981.PubMedCrossRefGoogle Scholar
  49. 49.
    Thorner MO, Perryman RL, Cronin MJ, et al: Acromegaly with somatotroph hyperplasia: Successful treatment by resection of a pancreatic tumor secreting a growth hormone (GH) releasing factor (GRF). J Clin Invest 70: 965, 1982.PubMedCrossRefGoogle Scholar
  50. 50.
    Rivier J, Spiess M, Thorner M, et al: Characterization of a growth hormone releasing factor from a human pancreatic islet tumour. Nature (Lond) 300:276, 1982.CrossRefGoogle Scholar
  51. 51.
    Guillemin R, Brazeau P, Bohlen P, et al: Growth hormone-releasing factor from a human pancreatic tumor that caused acromegaly. Science 218:585, 1982.PubMedCrossRefGoogle Scholar
  52. 52.
    Mayo KE, Vale W, Rivier J, et al: Expression cloning and sequencing of a cDNA encoding human growth hormone releasing factor. Nature (Lond) 306:86, 1983.CrossRefGoogle Scholar
  53. 53.
    Gubler U, Monahan JJ, Lomedico PT, et al: Cloning and sequence analysis of cDNA for the precursor of human growth hormone-releasing factor, somatocrinin. Proc Natl Acad Sci USA 80:4311, 1983.PubMedCrossRefGoogle Scholar
  54. 54.
    Ch’ng JLC, Christofides ND, Kraenzlin ME, et al: Growth hormone secretion dynamics in a patient with ectopic growth hormone-releasing factor production. Am J Med 79:135, 1985.PubMedCrossRefGoogle Scholar
  55. 55.
    Schulte HM, Benker G, Windeck R, et al: Failure to respond to growth hormone releasing hormone (GHRH) in acromegaly due to a GHRH secreting pancreatic tumor: Dynamics of multiple endocrine testing. J Clin Endocrinol Metab 61:585, 1985.PubMedCrossRefGoogle Scholar
  56. 56.
    Wilson DM, Ceda GP, Bostwick DG, et al: Acromegaly and Zollinger-Ellison syndrome secondary to an islet cell tumor: Characterization and quantification of plasma and tumor human growth hormone-releasing factor. J Clin Endocrinol Metab 59:1002, 1984.PubMedCrossRefGoogle Scholar
  57. 57.
    Thorner MO, Frohman LA, Leong DA, et al: Extrahypothalamic growth-hormone-releasing factor (GRF) secretion is a rare cause of acromegaly: Plasma GRF levels in 177 acromegalic patients. J Clin Endocrinol Metab 59:846, 1984.PubMedCrossRefGoogle Scholar
  58. 58.
    McGrath P: Volume and histology of the human pharyngeal hypophysis. Aust NZ J Surg 37:16, 1967.CrossRefGoogle Scholar
  59. 59.
    Melchionna RH, Moore RA: The pharyngeal pituitary gland. Am J Pathol 14:763, 1938.PubMedGoogle Scholar
  60. 60.
    Boyd JS: Observations in the human pharyngeal hypophysis. J Endocrinol 14:66, 1956.PubMedCrossRefGoogle Scholar
  61. 61.
    Rasmussen P, Lindholm J: Ectopic pituitary adenomas. Clin Endocrinol (Oxf) 11:69, 1979.CrossRefGoogle Scholar
  62. 62.
    Corenblum B, Leblanc FE, Watanabe M: Acromegaly with an adenomatous pharyngeal pituitary. JAMA 243:1456, 1980.PubMedCrossRefGoogle Scholar
  63. 63.
    Warner BA, Santen RJ, Page RB: Growth hormone and prolactin secretion by a tumor of the pharyngeal pituitary. Ann Intern Med 96:65, 1982.PubMedGoogle Scholar
  64. 64.
    Kammer H, George R: Cushing’s disease in a patient with an ectopic pituitary adenoma. JAMA 246:2722, 1981.PubMedCrossRefGoogle Scholar
  65. 65.
    Kovacs K, Horvath E: Pituitary adenomas. Pathologic aspects. In Tolis G, Labrie F, Martin JB, Naftolin F (eds): Clinical Neuroendocrinology. A Pathophysiological Approach. Raven Press, New York, 1979, p. 367.Google Scholar
  66. 66.
    Kovacs K, Horvath E, Pritzker KPH, et al: Pituitary growth hormone cell adenoma with cytoplasmic tubular aggregates in the capillary endothelium. Acta Neuropathol (Berl) 37:77, 1977.CrossRefGoogle Scholar
  67. 67.
    Horvath E, Kovacs K: Ultrastructural classification of pituitary adenomas. Can J Neurol Sci 3:9, 1976.PubMedGoogle Scholar
  68. 68.
    Kovacs K, Horvath E, Ryan N: Immunocytology of the human pituitary. In Delellis RA (ed): Diagnostic Immunocytochemistry. Masson USA, New York, 1981, p. 17.Google Scholar
  69. 69.
    Halmi NS, Duello T: “Acidophilic” pituitary tumor. A reappraisal with differential staining and immunocytochemical techniques. Arch Pathol Lab Med 100:346, 1976.PubMedGoogle Scholar
  70. 70.
    Halmi NS: Immunostaining of growth hormone cells and prolactin cells in paraffin-embedded and stored or previously stained material. J Histochem Cytochem 26:486, 1978.PubMedCrossRefGoogle Scholar
  71. 71.
    Kovacs K, Horvath E, Killinger DW, et al: Growth hormone producing pituitary adenoma with giant secretory granules. Acta Neuropathol 46:239, 1979.PubMedCrossRefGoogle Scholar
  72. 72.
    Trouillas J, Girod C, Lheritier M, et al: Morphological and biochemical relationships in 31 human pituitary adenomas with acromegaly. Virchows Arch Pathol Anat 389:127, 1980.PubMedGoogle Scholar
  73. 73.
    Zimmerman EA, Defendini R, Frantz AG: Prolactin and growth hormone in patients with pituitary adenomas. A correlative study of hormone in tumor and plasma by immunoperoxidase technique and radioimmunoassay. J Clin Endocrinol Metab 38:579, 1974.CrossRefGoogle Scholar
  74. 74.
    Corenblum B, Sirek AMT, Horvath E, et al: Human mixed somatotrophic and lactotrophic pituitary adenoma. J Clin Endocrinol Metab 42:857, 1976.PubMedCrossRefGoogle Scholar
  75. 75.
    Horvath E, Kovacs K, Singer W, et al: Acidophil stem cell adenoma of the human pituitary. Arch Pathol Lab Med 101:594, 1977.PubMedGoogle Scholar
  76. 76.
    Horvath E, Kovacs K, Singer W, Smyth HS, et al: Acidophil stem cell adenoma of the human pituitary. Clinico-pathological analysis of 15 cases. Cancer 47:761, 1981.PubMedCrossRefGoogle Scholar
  77. 77.
    Haigler ED, Hershman JM, Meador CK: Pituitary gigantism: A case report and review. Arch Intern Med 132:588, 1973.PubMedCrossRefGoogle Scholar
  78. 78.
    Prezio JA, Griffin JE, O’Brien JJ: Acromegalic gigantism: The Buffalo giant. Am J Med 31:966, 1961.PubMedCrossRefGoogle Scholar
  79. 79.
    Humberd CD: Gigantism: Report of a case. JAMA 108:544, 1937.Google Scholar
  80. 80.
    Gray H: The Minneapolis giant. Ann Intern Med 10:1669, 1937.Google Scholar
  81. 81.
    Levin SR, Hofeldt FD, Becker N, et al: Hypersomatotropism and acanthosis nigricans in two brothers. Arch Intern Med 134:365, 1974.PubMedCrossRefGoogle Scholar
  82. 82.
    Curth HO: Pigmentary changes of the skin associated with internal diseases. Postgrad Med 41:439, 1967.PubMedGoogle Scholar
  83. 83.
    Fitzpatrick TB, et al: Dermatology in General Medicine. McGraw-Hill, New York, 1971, p. 1447.Google Scholar
  84. 84.
    Courville C, Mason VR: The heart in acromegaly. Arch Intern Med 61:704, 1938.Google Scholar
  85. 85.
    Hejtmancik MR, Bradfield JY Jr, Herrmann GR: Acromegaly and the heart: A clinical and pathologic study. Ann Intern Med 34:1445, 1951.PubMedGoogle Scholar
  86. 86.
    Pepine CJ, Aloia J: Heart muscle disease in acromegaly. Am J Med 48:530, 1970.PubMedCrossRefGoogle Scholar
  87. 87.
    McGuffin WL, Sherman BM, Roth J, et al: Acromegaly and cardiovascular disorders: A prospective study. Ann Intern Med 81:11, 1974.PubMedGoogle Scholar
  88. 88.
    Ikkos D, Luft R, Sjogren B: Body water and sodium in patients with acromegaly. J Clin Invest 33:989, 1954.PubMedCrossRefGoogle Scholar
  89. 89.
    Strauch G, Vallotton MB, Touitou Y, et al: The renin-angiotensin-aldosterone system in normotensive and hypertensive patients with acromegaly. N Engl J Med 287:795, 1972.PubMedCrossRefGoogle Scholar
  90. 90.
    Cain JP, Williams GH, Dluhy RG: Plasma renin activity and aldosterone secretion in patients with acromegaly. / Clin Endocrinol Metab 34:73, 1972.CrossRefGoogle Scholar
  91. 91.
    Hamwi GJ, Skillman TG, Tufts KC Jr: Acromegaly. Am J Med 29:690, 1960.PubMedCrossRefGoogle Scholar
  92. 92.
    Jonas EA, Aloia JF, Lane FJ: Evidence of subclinical heart muscle dysfunction in acromegaly. Chest 67:190, 1975.PubMedCrossRefGoogle Scholar
  93. 93.
    Savage DD, Henry WL, Eastman RC, et al: Echocardiographic assessment of cardiac anatomy and function in acromegalic patients. Am J Med 67:823, 1979.PubMedCrossRefGoogle Scholar
  94. 94.
    Smallridge RC, Rajfer S, Davia J, et al: Acromegaly and the heart: An echocardiographic study. Am J Med 66:22, 1979.PubMedCrossRefGoogle Scholar
  95. 95.
    Savage DD, Eastman RC, Henry WL, et al: Echocardiographic evaluation of acromegalic patients (abstract). Circulation 54(suppl II):22, 1976.Google Scholar
  96. 96.
    Martins JB, Kerber RE, Sherman BM, et al: Cardiac size and function in acromegaly. Circulation 56:863, 1977.PubMedGoogle Scholar
  97. 97.
    O’Duffy JD, Randall RV, MacCarty CS: Median neuropathy (carpal-tunnel syndrome) in acromegaly. A sign of endocrine overactivity. Ann Intern Med 78:379, 1973.PubMedGoogle Scholar
  98. 98.
    Klijn JGM, Lamberts SWJ, de Jong FH, et al: Interrelation between tumour size, age, plasma growth hormone and incidence of extrasellar extension in acromegalic patients. Acta Endocrinol (Copenh) 95:289, 1980.Google Scholar
  99. 99.
    Epstein N, Whelan M, Benjamin V: Acromegaly and spinal stenosis: Case report. J Neurosurg 56:145, 1982.PubMedCrossRefGoogle Scholar
  100. 100.
    Mastaglia FL, Barwick DD, Hall R: Myopathy in acromegaly. Lancet 2:907, 1970.PubMedCrossRefGoogle Scholar
  101. 101.
    Lundberg PO, Osterman PO, Stalberg E: Neuromuscular signs and symptoms in acromegaly. In Walton JN, Canal N, Scarlata G, et al (eds): First International Congress on Muscle Disease, Milan, Italy. Excerpta Medica, Amsterdam, 1970, p. 531.Google Scholar
  102. 102.
    Pickett JBE III, Layzer RB, Levin SR, et al: Neuromuscular complications of acromegaly. Neurology (NY) 25:638, 1975.Google Scholar
  103. 103.
    Southwick JP, Katz J: Unusual airway difficulty in the acromegalic patient-Indications for tracheostomy. Anesthesiology 51:72, 1979.PubMedCrossRefGoogle Scholar
  104. 104.
    Ovassapian A, Doka JC, Ramsa DE: Acromegaly-Use of fiberoptic laryngoscopy to avoid tracheostomy. Anesthesiology 54:429, 1981.PubMedCrossRefGoogle Scholar
  105. 105.
    Perks WH, Horrocks PM, Cooper RA, et al: Sleep apnoea in acromegaly. Br Med J 280:894, 1980.PubMedCrossRefGoogle Scholar
  106. 106.
    Hart TB, Radow SK, Blackard WG, et al: Sleep apnea in active acromegaly. Arch Intern Med 145:865, 1985.PubMedCrossRefGoogle Scholar
  107. 107.
    Cadieux RJ, Kales A, Santen RJ, et al: Endoscopic findings in sleep apnea associated with acromegaly. J Clin Endocrinol Metab 55:18, 1982.PubMedCrossRefGoogle Scholar
  108. 108.
    Sober AJ, Gorden P, Roth J, et al: Visceromegaly in acromegaly. Arch Intern Med 134:415, 1974.PubMedCrossRefGoogle Scholar
  109. 109.
    Thomson JA, McCrossan J, Mason DK: Salivary gland enlargement in acromegaly. Clin Endocrinol (Oxf) 3:1, 1974.CrossRefGoogle Scholar
  110. 110.
    Jadresic A, Banks LM, Child DF, et al: The acromegaly syndrome. Relation between clinical features, growth hormone values and radiological characteristics of the pituitary tumours. Q J Med 202:189, 1982.Google Scholar
  111. 111.
    Gordon DA, Hill FM, Ezrin C: Acromegaly: A review of 100 cases. Can Med Assoc J 87:1106, 1962.PubMedGoogle Scholar
  112. 112.
    Lawrence JH, Tobias CA, Linfoot JA, et al: Successful treatment of acromegaly: Metabolic clinical studies in 145 patients. J Clin Endocrinol Metab 31:180, 1970.PubMedCrossRefGoogle Scholar
  113. 113.
    Tyrrell JB, Wilson CB: Pituitary syndromes. In Friesen SR (ed): Surgical Endocrinology. Clinical Syndromes. JB Lippincott, Philadelphia, 1978, p. 304.Google Scholar
  114. 114.
    De Pablo F, Eastman RC, Roth J, et al: Plasma prolactin in acromegaly before and after treatment. J Clin Endocrinol Metab 53:344, 1981.PubMedCrossRefGoogle Scholar
  115. 115.
    Ezrin C, Kovacs K, Horvath E: Hyperprolactinemia: morphologic and clinical considerations. Med Clin North Am 62:393, 1978.PubMedGoogle Scholar
  116. 116.
    Tolis G, Bertrand G, Carpenter S, et al: Acromegaly and galactorrhea-amenorrhea with two pituitary adenomas secreting growth hormone or prolactin. Ann Intern Med 89:345, 1978.PubMedGoogle Scholar
  117. 117.
    Kanie N, Kageyama N, Kuwayama A, et al: Pituitary adenomas in acromegalic patients: An immunohistochemical and endocrinological study with special reference to prolactinsecreting adenoma. J Clin Endocrinol Metab 57:1093, 1983.PubMedCrossRefGoogle Scholar
  118. 118.
    Spitz IM, Barzilai D, Luboshitzky R: Diminished prolactin reserve in acromegaly. Metabolism 29:880, 1980.PubMedCrossRefGoogle Scholar
  119. 119.
    Tolis G, Kovacs L, Friesen H, et al: Dynamic evaluation of growth hormone (GH) and prolactin (hPRL) secretion in active acromegaly with high and low GH output. Acta Endocrinol (Copenh) 78:251, 1975.Google Scholar
  120. 120.
    Tourniaire J, Trouillas J, Chalendar D, et al: Somatotropic adenoma manifested by galactorrhea without acromegaly. J Clin Endocrinol Metab 61:451, 1985.PubMedCrossRefGoogle Scholar
  121. 121.
    De Pablo F, Eastman RC, Roth J, et al: Plasma prolactin in acromegaly before and after treatment. J Clin Endocrinol Metab 53:344, 1981.PubMedCrossRefGoogle Scholar
  122. 120.
    Tsuchiya H, Onishi T, Takamoto S, et al: Prolactin secretion in acromegalic patients before and after selective adenomectomy. J Clin Endocrinol Metab 61:104, 1985.PubMedCrossRefGoogle Scholar
  123. 123.
    Cobb WE, Reichlin S, Jackson IMD: Growth hormone secretory status is a determinant of the thyrotropin response to thyrotropin-releasing hormone in euthyroid patients with hypothalamic-pituitary disease. J Clin Endocrinol Metab 52:324, 1981.PubMedCrossRefGoogle Scholar
  124. 124.
    Root AW, Snyder PJ, Rezvani I, et al: Inhibition of thyrotropin-releasing hormone-mediated secretion of thyrotropin by human growth hormone. J Clin Endocrinol Metab 36:103, 1973.PubMedCrossRefGoogle Scholar
  125. 125.
    Lamberg BA, Pelkonen R, Aro A, et al: Thyroid function in acromegaly before and after transsphenoidal hypophysectomy followed by cryoapplication. Acta Endocrinol (Copenh) 82:254, 1976.Google Scholar
  126. 126.
    Lamberg BA, Ripatti J, Gordin A, et al: Chromophobe pituitary adenoma with acromegaly and TSH-induced hyperthyroidism associated with parathyroid adenoma: Acromegaly and parathyroid adenoma. Acta Endocrinol (Copenh) 60:157, 1969.Google Scholar
  127. 127.
    Kovacs K, Horvath E, Ezrin C, et al: Adenoma of the human pituitary producing growth hormone and thyrotropin. A histologic, immunocytologic and fine structural study. Virchows Arch Pathol Anat 394:59, 1982.Google Scholar
  128. 128.
    Hamilton CR Jr, Maloof F: Acromegaly and toxic goiter. Cure of the hyperthyroidism and acromegaly by proton-beam partial hypophysectomy. J Clin Endocrinol Metab 35:659, 1972.PubMedCrossRefGoogle Scholar
  129. 129.
    Horn K, Erhardt F, Fahlbusch R, et al: Recurrent goiter, hyperthyroidism, galactorrhea and amenorrhea due to a thyrotropin and prolactin-producing pituitary tumor. / Clin Endocrinol Metab 43:137, 1976.CrossRefGoogle Scholar
  130. 130.
    Waldhausl W, Bratusch-Marrain P, Nowotny P, et al: Secondary hyperthyroidism due to thyrotropin hyperthyroidism due to throtropin hypersecretion: study of pituitary tumor morphology and thyrotropin chemistry and release. J Clin Endocrinol Metab 49:879, 1979.PubMedCrossRefGoogle Scholar
  131. 131.
    Goldfine ID, Lawrence AM: Hypopituitarism in acromegaly. Arch Intern Med 130:720, 1972.PubMedCrossRefGoogle Scholar
  132. 132.
    Roth J, Glick SM, Cuatrecasas P, et al: Acromegaly and other disorders of growth hormone secretion: Combined clinical staff conference at the National Institutes of Health. Ann Intern Med 66:760, 1967.PubMedGoogle Scholar
  133. 133.
    Inada M, Sterline K: Thyroxine turnover and transport in active acromegaly. J Clin Endocrinol 27:1019, 1967.CrossRefGoogle Scholar
  134. 134.
    Cerasi E, Luft R: Insulin response to glucose loading in acromegaly. Lancet 2:769, 1964.PubMedCrossRefGoogle Scholar
  135. 135.
    Sönksen PH, Greenwood FC, Ellis JP, et al: Changes of carbohydrate tolerance in acromegaly with progress of the disease and in response to treatment. J Clin Endocrinol 27:1418, 1967.CrossRefGoogle Scholar
  136. 136.
    Linfoot JA, Chong CY, Lawrence JH, et al: Acromegaly. In Li CH (ed): Hormonal Proteins and Peptides. Vol. 111. Academic Press, New York, 1975, p. 191.Google Scholar
  137. 137.
    Wass JAH, Cudworth AG, Bottazzo GF, et al: An assessment of glucose intolerance in acromegaly and its response to medical treatment. Clin Endocrinol (Oxf) 12:53, 1980.CrossRefGoogle Scholar
  138. 138.
    Muggeo M, Bar RS, Roth J, et al: The insulin resistance of acromegaly: Evidence for two alterations in the insulin receptor on circulating monocytes. J Clin Endocrinol Metab 48:17, 1979.PubMedCrossRefGoogle Scholar
  139. 139.
    Muggeo M, Saviolakis GA, Businaro V, et al: Insulin receptor on monocytes from patients with acromegaly and fasting hyperglycemia. J Clin Endocrinol Metab 56:733, 1983.PubMedCrossRefGoogle Scholar
  140. 140.
    Hitman GA, Katz J, Lytras N, et al: Are there genetic determinants for the glucose intolerance of acromegaly? Clin Endocrinol (Oxf) 23:817, 1985.CrossRefGoogle Scholar
  141. 141.
    Nadarajah A, Hartog M, Redfern B, et al: Calcium metabolism in acromegaly. Br Med J 4:797, 1968.PubMedCrossRefGoogle Scholar
  142. 142.
    Sigurdsson G, Nunziata V, Reiner M, et al: Calcium absorption and excretion in the gut in acromegaly. Clin Endocrinol (Oxf) 2:187, 1973.CrossRefGoogle Scholar
  143. 143.
    Spanos E, Barrett D, MacIntyre I, et al: Effect of growth hormone on vitamin D metabolism. Nature (Lond) 273:246, 1978.CrossRefGoogle Scholar
  144. 144.
    Spencer EM, Tobiassen O: The mechanism of the action of growth hormone on vitamin D metabolism in the rat. Endocrinology 108:1064, 1981.PubMedCrossRefGoogle Scholar
  145. 145.
    Brown DJ, Spanos E, MacIntyre I: Role of pituitary hormones in regulating renal vitamin D metabolism in man. Br Med J 280:277, 1980.PubMedCrossRefGoogle Scholar
  146. 146.
    Burnstein S, Chen IW, Tsang RC: Effects of growth hormone replacement therapy on 1,25-dihydroxyvitamin D and calcium metabolism. J Clin Endocrinol Metab 56:1246, 1983.CrossRefGoogle Scholar
  147. 147.
    Chipman JJ, Zerwekh J, Nicar M, et al: Effect of growth hormone administration: reciprocal changes in serum 1,25-dihydroxyvitamin D and intestinal calcium absorption. J Clin Endocrinol Metab 51:321, 1980.PubMedCrossRefGoogle Scholar
  148. 148.
    Gertner JM, Tamborlane WV, Hintz RL, et al: The effects on mineral metabolism of overnight growth hormone infusion in growth hormone deficiency. J Clin Endocrinol Metab 53:818, 1981.PubMedCrossRefGoogle Scholar
  149. 149.
    Camanni F, Massara F, Losanna O, et al: Increased renal tubular reabsorption of phosphate in acromegaly. J Clin Endocrinol Metab 28:999, 1968.PubMedCrossRefGoogle Scholar
  150. 150.
    Takamoto S, Tsuchiya H, Onishi T, et al: Changes in calcium homeostasis in acromegaly treated by pituitary adenomectomy. J Clin Endocrinol Metab 61:7, 1985.PubMedCrossRefGoogle Scholar
  151. 151.
    Aloia JF, Petrak Z, Ellis K, et al: Body composition and skeletal metabolism following pituitary irradiation in acromegaly. Am J Med 61:59, 1976.PubMedCrossRefGoogle Scholar
  152. 152.
    Wermer P: Genetic aspects of adenomatosis endocrine glands. Am J Med 16:363, 1954.PubMedCrossRefGoogle Scholar
  153. 153.
    Farhi F, Dikman SH, Lawson W: Paragangliomatosis associated with multiple endocrine adenomas. Arch Pathol Lab Med 100:495, 1976.PubMedGoogle Scholar
  154. 154.
    German WJ, Flanigan S: Pituitary adenomas: a follow-up study of the Cushing series. Clin Neurosurg 10:72, 1964.PubMedGoogle Scholar
  155. 155.
    Kadowaki S, Baba Y, Kakita T, et al: A case of acromegaly associated with pheochromocytoma. [In Japanese.] Saishin-Igaku 31:1402, 1976.Google Scholar
  156. 157.
    Miller GL, Wynn J: Acromegaly, pheochromocytoma, toxic goiter, diabetes mellitus, and endometriosis. Arch Intern Med 127:299, 1971.PubMedCrossRefGoogle Scholar
  157. 158.
    Anderson RJ, Lufkin EG, Sizemore GW, et al: Acromegaly and pituitary adenoma with phaeochromocytoma: A variant of multiple endocrine neoplasia. Clin Endocrinol (Oxf) 14:605, 1981.CrossRefGoogle Scholar
  158. 159.
    Tolis G, Koutsilieris M, Bertrand G: Endocrine diagnosis of growth hormone-secreting pituitary tumors. Prog Endocrinol Res Ther 1:145, 1984.Google Scholar
  159. 160.
    Daggett PR, Nabarro JDN: Measurement of the 24 hour integrated plasma concentration of growth hormone, in assessing the response of acromegalic patients to treatment. Clin Endocrinol (Oxf) 7:437, 1977.CrossRefGoogle Scholar
  160. 161.
    Wass JAH, Thorner MO, Morris DV, et al: Long-term treatment of acromegaly with bromocriptine. Br Med J 1:875, 1977.PubMedCrossRefGoogle Scholar
  161. 162.
    Job JC, Sizonenko PC: Serum growth hormone (GH) in oral glucose test (OGT) in children. Comparison with insulin and arginine stimulation tests. In Second International Symposium on Growth Hormone, Milano, Italy. Excerpta Medica, Amsterdam, 1972, p. 46. (Abst.)Google Scholar
  162. 163.
    Lawrence AM, Wilber JF, Hagen TC: The pituitary and primary hypothyroidism. Enlargement and unusual growth hormone secretory responses. Arch Intern Med 132:327, 1973.PubMedCrossRefGoogle Scholar
  163. 164.
    Clemmons DR, Van Wyk JJ, Ridgway EC, et al: Evaluation of acromegaly by radioimunoassay of somatomedin-C. N Engl J Med 301:1138, 1979.PubMedCrossRefGoogle Scholar
  164. 165.
    Mims RB, Bethune JE: Acromegaly with normal fasting growth hormone concentrations but abnormal growth hormone regulation. Ann Intern Med 81:781, 1974.PubMedGoogle Scholar
  165. 166.
    Daughaday WH, Salmon WD, Alexander F: Sulfation factor activity of sera from patients with pituitary disorders. J Clin Endocrinol Metab 19:743, 1959.PubMedCrossRefGoogle Scholar
  166. 167.
    Furlanetto RW, Underwood LE, Van Wyk JJ, et al: Estimation of somatomedin-C levels in normals and patients with pituitary disease by radioimmunoassay. / Clin Invest 60:648, 1977.CrossRefGoogle Scholar
  167. 168.
    Cohen KL, Nissley SP: The serum half-life of somatomedins: Evidence for growth hormone dependence. Acta Endocrinol (Copenh) 83:243, 1976.Google Scholar
  168. 169.
    Rieu M, Girard F, Bricaire H, et al: The importance of insulin-like growth factor (somatomedin) measurements in the diagnosis and surveillance of acromegaly. J Clin Endocrinol Metab 55:147, 1982.PubMedCrossRefGoogle Scholar
  169. 170.
    Wass JAH, Clemmons DR, Underwood LE, et al: Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clin Endocrinol (Oxf) 17:369, 1982.CrossRefGoogle Scholar
  170. 171.
    Irie M, Tsushima T: Increase in serum GH after TRH injection in patients with acromegaly and gigantism. J Clin Endocrinol Metab 35:97, 1972.PubMedCrossRefGoogle Scholar
  171. 172.
    Jaquet P, Codaccioni JL, Oliver C, et al: Fourth International Congress of Endocrinology, Washington D.C., June 18–24, 1972. Excerpta Medica International Congress Series No. 256. (Abst. 221.)Google Scholar
  172. 173.
    Schalch DS, Gonzalez-Barcena D, Kastin AJ, et al: Abnormalities in the release of TSH in response to thyrotropin-releasing hormone (TRH) in patients with disorders of the pituitary, hypothalamus and basal ganglia. J Clin Endocrinol Metab 35:609, 1972.PubMedCrossRefGoogle Scholar
  173. 174.
    Faglia G, Beck-Peccoz P, Ferrari P, et al: Plasma growth hormone response to thyrotropin-releasing hormone in patients with active acromegaly. J Clin Endocrinol Metab 36:1259, 1973.PubMedCrossRefGoogle Scholar
  174. 175.
    Rubin AL, Levin SR, Berstein RI, et al: Stimulation of growth hormone by luteinizing hormone-releasing hormone in active acromegaly. J Clin Endocrinol Metab 37:160, 1973.PubMedCrossRefGoogle Scholar
  175. 176.
    Hulting AL, Werner S, Wersäll J, et al: Normal growth hormone secretion is rare after microsurgical normalization of growth hormone levels in acromegaly. Acta Med Scand 212:401, 1982.PubMedCrossRefGoogle Scholar
  176. 177.
    Liuzzi A, Chiodini PG, Botalla L, et al: Growth hormone (GH)-releasing activity of TRH and GH-lowering effect of dopaminergic drugs in acromegaly: Homogeneity in the two responses. J Clin Endocrinol Metab 39:871, 1974.PubMedCrossRefGoogle Scholar
  177. 178.
    Chiodini PG, Liuzzi A, Botalla L, et al: Stable reduction of plasma growth hormone (HGH) levels during chronic administration of 2-Br-α-ergocryptine (CB-154) in acromegalic patients. J Clin Endocrinol Metab 40:705, 1975.PubMedCrossRefGoogle Scholar
  178. 179.
    Jackson IMD: Diagnostic tests for the evaluation of pituitary tumors. In Post KD, Jackson IMD, Reichlin S (eds): The Pituitary Adenoma Plenum, New York, 1980, p. 219.Google Scholar
  179. 180.
    Evain-Brion D, Garnier P, Schimpff RM, et al: Growth hormone response to thyrotropin-releasing hormone and oral glucose-loading tests in tall children and adolescents. J Clin Endocrinol Metab 56:429, 1983.PubMedCrossRefGoogle Scholar
  180. 181.
    Maeda K, Rata Y, Ohgo S, et al: Growth hormone and prolactin release after injection of thyrotropin-releasing hormone in patients with depression. J Clin Endocrinol Metab 40:501, 1975.PubMedCrossRefGoogle Scholar
  181. 182.
    Maeda M, Kuzuya N, Masuyama Y, et al: Changes in serum triiodothyronine, thyroxine and thyrotropin during treatment with thyroxine in severe primary hypothyroidism. J Clin Endocrinol Metab 43:10, 1976.PubMedCrossRefGoogle Scholar
  182. 183.
    Gild AD I, Dickerman Z, Weizman R: Abnormal GH response to LH-RH and TRH in adolescent schizophrenic boys. Am J Psychiatry 138:357, 1981.Google Scholar
  183. 184.
    Collu R, Leboeuf G, Letarte J, et al: Increase in plasma growth hormone levels following thyrotropin-releasing hormone injection in children with primary hypothyroidism. / Clin Endocrinol Metab 44:743, 1977.CrossRefGoogle Scholar
  184. 185.
    Faggiano M, Criscuolo T, Graziani M, et al: Persistent TRH-induced growth hormone release after short-term and long-term L-thyroxine replacement therapy in primary congenital hypothyroidism. Clin Endocrinol (Oxf) 23:61, 1985.CrossRefGoogle Scholar
  185. 186.
    Dunn PJ, Donald RA, Espiner EA: Bromocriptine suppression of plasma growth hormone in acromegaly. Clin Endocrinol (Oxf) 7:273, 1977.CrossRefGoogle Scholar
  186. 187.
    Tolis G, McKenzie JM, Martin JB, et al: Growth hormone secreting pituitary tumors: Clinical presentation, diagnostic tests and therapeutic modalities. In Tolis G, Labrie F, Martin JB, Naftolin F, (eds): Clinical Neuroendocrinology: A Pathophysiologic Approach. Raven Press, New York, 1979, p. 437.Google Scholar
  187. 188.
    Losa M, Schopohl J, Stalla GK, et al: Growth hormone releasing factor test in acromegaly: Comparison with other dynamic tests. Clin Endocrinol (Oxf) 23:99, 1985.CrossRefGoogle Scholar
  188. 189.
    Golde DW, Herschman HR, Lusis AJ, et al: Growth factors. Ann Intern Med 92:650, 1980.Google Scholar
  189. 190.
    Ashcraft MW, Hartzband PI, Van Herle AJ, et al: A unique growth factor in patients with acromegaloidism. J Clin Endocrinol Metab 57:272, 1983.PubMedCrossRefGoogle Scholar
  190. 191.
    Cardoso ER, Peterson EW: Pituitary apoplexy: A review. Neurosurgery 14:363, 1984.PubMedCrossRefGoogle Scholar
  191. 192.
    Rigolosi RS, Schwartz E, Glick SM: Occurrence of growth-hormone deficiency in acromegaly as a result of pituitary apoplexy. N Engl J Med 279:362, 1968.PubMedCrossRefGoogle Scholar
  192. 193.
    Lawrence AM: Hypothalamic hypopituitarism after pituitary apoplexy in acromegaly. Arch Intern Med 137:1134, 1977.PubMedCrossRefGoogle Scholar
  193. 194.
    Werner PL, Shah JH, Kukreja SC, et al: Recurrence of acromegaly after pituitary apoplexy. JAMA 247:2816, 1982.PubMedCrossRefGoogle Scholar
  194. 195.
    Wright AD, Hill DM, Lowy C, et al: Mortality in acromegaly. Q J Med 39:1, 1970.PubMedGoogle Scholar
  195. 196.
    Brennan MD, Jackson IT, Keller EE, et al: Multidisciplinary management of acromegaly and its deformities. JAMA 253:682, 1985.PubMedCrossRefGoogle Scholar
  196. 197.
    Whitehead EM, Shalet SM, Davies D, et al: Pituitary gigantism: A disabling condition. Clin Endocrinol (Oxf) 17:271, 1982.CrossRefGoogle Scholar
  197. 198.
    Klein I, Parveen G, Gavaler JS, et al: Colonic polyps in patients with acromegaly. Ann Intern Med 97:27, 1982.PubMedGoogle Scholar
  198. 199.
    Ituarte EA, Petrini J, Hershman JM, et al: Acromegaly and colon cancer. Ann Intern Med 101:627, 1984.PubMedGoogle Scholar
  199. 200.
    Baskin DS, Boggan JE, Wilson CB: Transsphenoidal microsurgical removal of growth hormone-secreting pituitary adenomas. A review of 137 cases. J Neurosurg 56:634, 1982.PubMedCrossRefGoogle Scholar
  200. 201.
    Richards SH, Thomas JP: Treatment of acromegaly by transethmoidal hypophysectomy. Q J Med 193:21, 1980.Google Scholar
  201. 202.
    Tucker HG, Grubb SR, Wigand JP, et al: The treatment of acromegaly by transsphenoidal surgery. Arch Intern Med 140:795, 1980.PubMedCrossRefGoogle Scholar
  202. 203.
    Besser GM, Wass JAH: The medical management of acromegaly. Secretory tumors of the pituitary gland. In Black PM, Zervas NT, Ridgway EC, et al. (eds): Progress in Endocrine Research and Therapy ,Vol. 1. Raven Press, New York, 1984, p. 155.Google Scholar
  203. 204.
    Stonesifer BD, Jordan RM, Kohler PO: Somatomedin C in treated acromegaly: Poor correlation with growth hormone and clinical response. J Clin Endocrinol Metab 53:931, 1981.PubMedCrossRefGoogle Scholar
  204. 205.
    Moses AC, Molitch ME, Sawin CT, et al: Bromocriptine therapy in acromegaly: Use in patients resistant to conventional therapy and effect on serum levels of somatomedin C. / Clin Endocrinol Metab 53:752, 1981.CrossRefGoogle Scholar
  205. 206.
    Nortier JWR, Croughs RJM, Thijssen JHH, et al: Bromocriptine therapy in acromegaly: Effects on plasma GH Levels, somatomedin-C levels and clinical activity. Clin Endocrinol (Oxf) 22:209, 1985.CrossRefGoogle Scholar
  206. 207.
    Laws ER JR: The neurosurgical management of acromegaly. Secretory tumors of the pituitary gland. In Black PM, Zervas NT, Ridgway EC, et al (eds), Progress in Endocrine Research and Therapy ,Vol. 1. Raven Press, New York, 1984, p. 169.Google Scholar
  207. 208.
    Hardy J, Somma M: Acromegaly: Surgical treatment by transsphenoidal microsurgical removal of the pituitary adenoma. In Tindall GT, Collins WF (eds): Clinical Management of Pituitary Disorders. Raven Press, New York, 1979, p. 209.Google Scholar
  208. 209.
    Tindall GT, Tindall SC: Transsphenoidal surgery for acromegaly: Long-term results in 50 patients. Secretory tumors of the pituitary gland. In Balck PM, Zervas NT, Ridgway EC, et al (eds): Progress in Endocrine Research and Therapy ,Vol. 1. Raven Press, New York, 1984, p. 175.Google Scholar
  209. 210.
    Schaison G, Couzinet B, Moatti N, et al: Critical study of the growth hormone response to dynamic tests and the insulin growth factor assay in acromegaly after microsurgery. Clin Endocrinol (Oxf) 18:541, 1983.CrossRefGoogle Scholar
  210. 211.
    Hardy J, Somma M, Vezina JL: Treatment of acromegaly: Radiation or surgery? In Morley JP (ed): Current Controversies in Neurosurgery. WB Saunders, Philadelphia, 1976, p. 377.Google Scholar
  211. 212.
    Laws ER, Piepgras DG, Randall RV, et al: Neurosurgical management of acromegaly. J Neurosurg 50:454, 1979.PubMedCrossRefGoogle Scholar
  212. 213.
    Roth J, Gorden P, Brace K: Efficacy of conventional pituitary irradiation in acromegaly. N Engl J Med 282:1385, 1970.PubMedCrossRefGoogle Scholar
  213. 214.
    Lawrence AM, Pinsky SM, Goldine ID: Conventional radiation therapy in acromegaly. Arch Intern Med 128:369, 1971.PubMedCrossRefGoogle Scholar
  214. 215.
    Eastman RC, Gorden P, Roth J: Conventional supervoltage irradiation is an effective treatment for acromegaly. J Clin Endocrinol Metab 48:931, 1979.PubMedCrossRefGoogle Scholar
  215. 216.
    Bloom B, Kramer S: Conventional radiation therapy in the management of acromegaly. Secretory tumors of the pituitary gland. In Black PM, Zervas NT, Ridgway EC, et al. (eds): Progress in Endocrine Research and Therapy ,Vol. 1. Raven Press, New York, 1984, p. 179.Google Scholar
  216. 217.
    Aloia JF, Archambeau JO: Hypopituitarism following pituitary irradiation for acromegaly. Horm Res 9:201 ,1977.CrossRefGoogle Scholar
  217. 218.
    Jenkins JS, Ash S, Bloom HJG: Endocrine function after external pituitary irradiation in patients with secreting and nonsecreting pituitary tumours. Q J Med 41:57, 1972.PubMedGoogle Scholar
  218. 219.
    Kanis JA, Gillingham FJ, Harris P, et al: Clinical and laboratory study of acromegaly. Assessment before and year after treatment. Q J Med 43:409, 1974.PubMedGoogle Scholar
  219. 220.
    Aristizabal S, Caldwell WL, Avila J: The relationship of time-dose fractionation factors to complications in the treatment of pituitary tumors by irradiation. Int J Radial Oncol Biol Phys 2:667, 1977.CrossRefGoogle Scholar
  220. 221.
    Harris JR, Levene MB: Visual complications following irradiation for pituitary adenomas and craniopharyngiomas. Radiology 120:167, 1976.PubMedGoogle Scholar
  221. 222.
    Kjellberg RN, Shintani A, Frantz AG, et al: Proton beam therapy in acromegaly. N Engl J Med 278:689, 1968.PubMedCrossRefGoogle Scholar
  222. 223.
    Kliman B, Kjellberg RN, Swisher B, et al: Proton beam therapy of acromegaly: A 20-year experience. Secretory tumors of the pituitary gland. In Black PM, Zervas NT, Ridgway EC, et al. (eds): Progress in Endocrine Research and Therapy ,Raven Press, New York, 1984, p. 191.Google Scholar
  223. 224.
    Kjellberg RN, Kliman B: Lifetime effectiveness-A system of therapy for pituitary adenomas, emphasizing Bragg peak proton hypophysectomy. In Recent Advances in the Diagnosis and Treatment of Pituitary Tumors. Linfoot JA (ed): Raven Press, New York, 1979, p. 269.Google Scholar
  224. 225.
    Linfoot JA: Heavy ion therapy: Alpha particle therapy of pituitary tumors. In Linfoot JA (ed): Recent Advances in the Diagnosis and Treatment of Pituitary Tumors. Raven Press, New York, 1979.Google Scholar
  225. 226.
    Linfoot JA, Garcia JF, Hoye SA, et al: Treatment of acromegaly. Proc R Soc Med 63:219, 1969.Google Scholar
  226. 227.
    Liuzzi A, Chiodini PG, Botalle L, et al: Decreased plasma growth hormone (GH) levels in acromegalics following CB 154 (2-Br-α-ergocryptine) administration. J Clin Endocrinol Metab 38:910, 1974.PubMedCrossRefGoogle Scholar
  227. 228.
    Parkes D: Bromocriptine. N Engl J Med 301:873, 1979.PubMedCrossRefGoogle Scholar
  228. 229.
    Besser GM, Wass JAH, Thorner MO: Acromegaly-results of long term treatment with bromocriptine. Acta Endocrinol (Copenh) (Suppl) 216:187, 1978.Google Scholar
  229. 230.
    Benker G, Sandman K, Tharandt L, et al: Gel filtration studies of serum growth hormone in acromegaly following bromocriptine administration. Horm Res 11:151, 1979.PubMedCrossRefGoogle Scholar
  230. 231.
    Besser GM, Thorner MO, Wass JAH, et al: Bromocriptine treatment of acromegaly. Q J Med 45:695, 1976.Google Scholar
  231. 232.
    Lindholm J, Riishede J, Vestergaard S, et al: No effect of bromocriptine in acromegaly. A controlled trial. N Engl J Med 304:1450, 1981.PubMedCrossRefGoogle Scholar
  232. 233.
    Cassar J, Mashiter K, Joplin GF: Bromocriptine treatment of acromegaly. Metabolism 26:539, 1977.PubMedCrossRefGoogle Scholar
  233. 234.
    Wass JAH, Clemmons DR, Underwood LE, et al: Changes in circulating somatomedin-C levels in bromocriptine-treated acromegaly. Clin Endocrinol (Oxf) 17:369, 1982.CrossRefGoogle Scholar
  234. 235.
    Chiba T, Chihara K, Minamitani N, et al: Effect of long term bromocriptine treatment on glucose intolerance in acromegaly. Horm Metab Res 14:57, 1982.PubMedCrossRefGoogle Scholar
  235. 236.
    Eskildsen PC, Svendsen PAA, Vang L, et al: Long-term treatment of acromegaly with bromocriptine. Acta Endocrinol (Copenh) 87:687, 1978.Google Scholar
  236. 237.
    Thorner MO, Besser GM, Wass JAH, et al: Bromocriptine in acromegaly. N Engl J Med 305:1092, 1981.PubMedCrossRefGoogle Scholar
  237. 238.
    Wass JAH, Moult PJA, Thorner MO, et al: Reduction of pituitary tumour size in patients with prolactinomas and acromegaly treated with bromocriptine with or without radiotherapy. Lancet 2:66, 1979.PubMedCrossRefGoogle Scholar
  238. 239.
    Wass JAH, Williams J, Charlesworth M, et al: Bromocriptine in the management of large pituitary tumours. Br Med J 284:1908, 1982.CrossRefGoogle Scholar
  239. 240.
    Kendall-Taylor P, Upstill-Goddard G, Cook D: Longterm pergolide treatment of acromegaly. Clin Endocrinol (Oxf) 19:711, 1983.CrossRefGoogle Scholar
  240. 241.
    Eskildsen PC, Hommel E, Buchhave J: The effect of a new ergoline derivative, CU 32-085, in the treatment of acromegaly. A controlled study. Clin Endocrinol (Oxf) 22:189, 1985.CrossRefGoogle Scholar
  241. 242.
    Besser GM, Mortimer CH, Carr D, et al: Growth hormone release inhibiting hormone in acromegaly. Br Med J 1:352, 1974.PubMedCrossRefGoogle Scholar
  242. 243.
    Yen SSC, Siler TM, Devane GW: Effect of somatostatin in patients with acromegaly. N Engl J Med 290:935, 1974.PubMedCrossRefGoogle Scholar
  243. 244.
    Lamberts SWJ, Oosterom R, Neufeld M, et al: The somatostatin analog SMS 201-995 induces long-acting inhibition of growth hormone secretion without rebound hypersecretion in acromegalic patients. J Clin Endocrinol Metab 60:1161, 1985.PubMedCrossRefGoogle Scholar
  244. 245.
    Lamberts SWJ, Uitterlinden P, Verschoor L, et al: Long-term treatment of acromegaly with the somatostatin analogue SMS 201-995. N Engl J Med 313:1576, 1985.PubMedCrossRefGoogle Scholar
  245. 246.
    Adelman LS: The Pathology of Pituitary Adenomas. In Post KD, Jackson IM, Reichlin S (eds): The Pituitary Adenoma ,Plenum Press, New York, 1980, pp. 47–62.Google Scholar
  246. 247.
    Reichlin S:Etiology of Pituitary Adenomas. In Post KD, Jackson IM, Reichlin S (eds): The Pituitary Adenoma ,Plenum Press, New York, 1980, pp. 29–46.Google Scholar

Copyright information

© Plenum Publishing Corporation 1987

Authors and Affiliations

  • C. R. Kannan
    • 1
    • 2
  1. 1.Division of Endocrinology and Metabolism Department of MedicineCook County HospitalChicagoUSA
  2. 2.University of Illinois at ChicagoChicagoUSA

Personalised recommendations